Gilead Sciences (GILD) EBT Margin Growth (3y) (2012 - 2026)
Gilead Sciences (GILD) EBT Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Margin Growth (3y) (Qtr) |
| 1 |
Gsk |
92,316,836.42 Bn |
92,316,831.46 Bn |
7.76 Bn |
67.00 |
| 2 |
Eli Lilly |
983.57 Bn |
978.29 Bn |
16.22 Bn |
2,272.00 |
| 3 |
Johnson & Johnson |
553.56 Bn |
531.50 Bn |
15.96 Bn |
3,105.00 |
| 4 |
AbbVie |
383.35 Bn |
374.00 Bn |
10.78 Bn |
304.00 |
| 5 |
Merck |
281.71 Bn |
276.06 Bn |
12.09 Bn |
-4,669.00 |
| 6 |
Amgen |
182.20 Bn |
170.16 Bn |
5.87 Bn |
-3,220.00 |
| 7 |
Gilead Sciences |
153.71 Bn |
145.98 Bn |
5.52 Bn |
1,660.00 |
| 8 |
Pfizer |
143.75 Bn |
130.98 Bn |
-1.21 Bn |
-3,734.00 |
| 9 |
Bristol Myers Squibb |
109.71 Bn |
99.25 Bn |
8.07 Bn |
377.00 |
| 10 |
Novartis Ag |
108.28 Bn |
107.60 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
1,660.00 |
| Dec 31, 2025 |
-127.00 |
| Sep 30, 2025 |
1,233.00 |
| Jun 30, 2025 |
1,029.00 |
| Mar 31, 2025 |
2,704.00 |
| Dec 31, 2024 |
1,815.00 |
| Sep 30, 2024 |
-3,366.00 |
| Jun 30, 2024 |
30.00 |
| Mar 31, 2024 |
-10,234.00 |
| Dec 31, 2023 |
-121.00 |
| Sep 30, 2023 |
2,033.00 |
| Jun 30, 2023 |
8,187.00 |
| Mar 31, 2023 |
-1,564.00 |
| Dec 31, 2022 |
-485.00 |
| Sep 30, 2022 |
6,132.00 |
| Jun 30, 2022 |
-1,838.00 |
| Mar 31, 2022 |
-4,681.00 |
| Dec 31, 2021 |
-705.00 |
| Sep 30, 2021 |
-128.00 |
| Jun 30, 2021 |
-771.00 |
